<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>3</IssueIDStart>
          <IssueIDEnd>3</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>9</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art22">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>73723</ArticleID>
            <ArticleDOI>10.1208/aapsj070372</ArticleDOI>
            <ArticleSequenceNumber>22</ArticleSequenceNumber>
            <ArticleTitle Language="En">Patent issues in drug development: Perspectives of a pharmaceutical scientist-attorney</ArticleTitle>
            <ArticleFirstPage>E723</ArticleFirstPage>
            <ArticleLastPage>E727</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>3</Month>
                <Day>15</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>3</Month>
                <Day>15</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>3</IssueIDStart>
              <IssueIDEnd>3</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Srikumaran</GivenName>
                  <FamilyName>Melethil</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>913-492-8185</Phone>
                  <Fax>913-888-1829</Fax>
                  <Email>melethils@umke.edu</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Schools of Pharmacy and Medicine</OrgDivision>
                <OrgName>University of Missouri-Kansas City</OrgName>
                <OrgAddress>
                  <Street>8428 Constance St</Street>
                  <Postcode>66215</Postcode>
                  <City>Lenexa</City>
                  <State>KS</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The major purpose of this article is to emphasize the need for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Economic incentives for drug discovery and development clash with societal needs for low-cost pharmaceuticals in the United States and all over the world. The Hatch-Waxman Act of 1984 was enacted to promote public health by balancing the interests of brand name and generic companies. Patent protection, which provides a monopoly for a limited time, is aimed to provide such incentives. Creation of patents requires the interaction between scientists and lawyers, an endeavor made difficult by the differing intellectual spheres of their respective disciplines. Therefore, in the first place, a thorough understanding of patent fundamentals among pharmaceutical scientists will help them work more efficiently with patent attorneys. Second, it will enable them to appreciate the strengths and weaknesses of individual patents, which is critical in developing strategies amidst the ongoing patent tug-of-war between brandname and generic companies.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>Hatch-Waxman Act</Keyword>
              <Keyword>Brand Drugs</Keyword>
              <Keyword>Generic Drugs</Keyword>
              <Keyword>Patent Strategies</Keyword>
              <Keyword>Paragraph IV certification</Keyword>
              <Keyword>ANDA</Keyword>
              <Keyword>Prozac</Keyword>
              <Keyword>Buspar</Keyword>
              <Keyword>Prilosec</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 27, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_73723.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>PW</Initials>
                    <FamilyName>Grubb</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <BookTitle>Patents for Chêmicals, Pharmaceuticals and Biotechnology</BookTitle>
                  <PublisherName>Oxford University Press</PublisherName>
                  <PublisherLocation>London, UK</PublisherLocation>
                  <FirstPage>273</FirstPage>
                  <LastPage>273</LastPage>
                </BibBook>
                <BibUnstructured>Grubb PW.<Emphasis Type="Italic">Patents for Chêmicals, Pharmaceuticals and Biotechnology</Emphasis>. London, UK: Oxford University Press.; 1999:273.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>PW</Initials>
                    <FamilyName>Grubb</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <BookTitle>Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy</BookTitle>
                  <PublisherName>Oxford University Press</PublisherName>
                  <PublisherLocation>London, UK</PublisherLocation>
                  <FirstPage>345</FirstPage>
                  <LastPage>345</LastPage>
                </BibBook>
                <BibUnstructured>Grubb PW.<Emphasis Type="Italic">Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy</Emphasis>. London, UK: Oxford University Press; 1999:345.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibUnstructured>Rea TS. Burns, Doane, Swecker &amp; Mathis LLP Web site. Methods of Maximizing Exclusivity for Pharmaceutical Products. Available at: http://www.burnsdoane.com/pubs/real.htm.Accessed September 29, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Mullin</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Priming the Pipeline</ArticleTitle>
                  <JournalTitle>Chem Eng News</JournalTitle>
                  <VolumeID>82</VolumeID>
                  <FirstPage>23</FirstPage>
                  <LastPage>42</LastPage>
                </BibArticle>
                <BibUnstructured>Mullin R. Priming the Pipeline.<Emphasis Type="Italic">Chem Eng News</Emphasis>. 2004;82:23–42.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>A Convergence of Science and Law. National Academy Press Web site. 2001. Available at: http://www.nap.edu/catalog/10174.html. Accessed September 29, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>GM</Initials>
                    <FamilyName>Levitt</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ChapterTitle Language="En">The drugs/biologics approval process</ChapterTitle>
                  <BibEditorName>
                    <Initials>KR</Initials>
                    <FamilyName>Pina</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>WL</Initials>
                    <FamilyName>Pines</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>A Practical Guide to Food and Drug Law Regulation</BookTitle>
                  <EditionNumber>2nd ed.</EditionNumber>
                  <PublisherName>Food and Drug Law Institute</PublisherName>
                  <PublisherLocation>Washington, DC</PublisherLocation>
                </BibChapter>
                <BibUnstructured>Levitt GM. The drugs/biologics approval process. In: Pina KR, Pines WL, eds.<Emphasis Type="Italic">A Practical Guide to Food and Drug Law Regulation</Emphasis>. 2nd ed. Washington, DC: Food and Drug Law Institute; 2002.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>DO</Initials>
                    <FamilyName>Beers</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <BookTitle>Generic and Innovator Drugs: A Guide to FDA Approval Requirements</BookTitle>
                  <EditionNumber>5th ed.</EditionNumber>
                  <PublisherName>Aspen Publishers</PublisherName>
                  <PublisherLocation>Frederick, MD</PublisherLocation>
                  <FirstPage>3</FirstPage>
                  <LastPage>24</LastPage>
                </BibBook>
                <BibUnstructured>Beers DO.<Emphasis Type="Italic">Generic and Innovator Drugs: A Guide to FDA Approval Requirements</Emphasis>. 5th ed. Frederick, MD: Aspen Publishers 1999:3–24.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Pressman</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <BookTitle>Patent It Yourself</BookTitle>
                  <EditionNumber>9th ed.</EditionNumber>
                  <PublisherName>Nolo Press</PublisherName>
                  <PublisherLocation>Berkeley, CA</PublisherLocation>
                </BibBook>
                <BibUnstructured>Pressman D.<Emphasis Type="Italic">Patent It Yourself</Emphasis>, 9th ed. Berkeley, CA: Nolo Press; 2002.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>RP</Initials>
                    <FamilyName>Merges</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PS</Initials>
                    <FamilyName>Menell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Lanley</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <BookTitle>Intellectual Property in the New Technological Age</BookTitle>
                  <PublisherName>Aspen Press</PublisherName>
                  <PublisherLocation>Frederick, MD</PublisherLocation>
                  <FirstPage>215</FirstPage>
                  <LastPage>274</LastPage>
                </BibBook>
                <BibUnstructured>Merges RP, Menell PS, Lanley MA.<Emphasis Type="Italic">Intellectual Property in the New Technological Age</Emphasis>. Frederick, MD: Aspen Press; 2003:215–274.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>Chisum DS, Jacobs MA, Bender M.<Emphasis Type="Italic">Understanding intellectual Property Law</Emphasis>. 1999: §2–175.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibUnstructured>Lilly v Barr. 222 F3d 973 (Fed Cir 2000).</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibUnstructured>Lilly v Barr. 251 F3d 955 (Fed Cir 2001).</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibUnstructured>In re Omeprazole Patent Litigation, 222 F Supp 2d 423 (S NY 2002).</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibUnstructured>In re Omeprazole Patent Litigation, 84 Fed Appx 76 (Fed Cir 2003).</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibUnstructured>Consumers Pay Billions a year Too much for Prilosec<Superscript>®</Superscript>. Available at: http://www.spancoalition.org/Drugs/drug4.htm.Accessed September 28, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibUnstructured>In re Buspirone Patent Litigation 185 F Supp 2d 340 (S NY 2002).</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibUnstructured>More than Heartburn at Stake in December 6 Prilosec<Superscript>®</Superscript> Trial, According to Stop Patient Abuse Now. Available at: http://www. spancoalition.org/MediaRelease/mediaadvisory 12.05.01.htm. Accessed September 28, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibUnstructured>Chan FM. Potential Blockbuster Drugs. Available at: http://ww.forbes.com/2003/10/08/cz-finc-1008sf.html. Accessed September 29, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Hughes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Moore</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Snyder</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <BookTitle>Napsterizing Pharmaceuticals: Access, Innovation, and Consumer Welfare</BookTitle>
                  <SeriesTitle Language="En">National Bureau of Economic Research Working paper</SeriesTitle>
                  <NumberInSeries>No. 9229</NumberInSeries>
                  <PublisherName>NBER</PublisherName>
                  <PublisherLocation>Cambridge, MA</PublisherLocation>
                </BibBook>
                <BibUnstructured>Hughes J, Moore M, Snyder E. Napsterizing Pharmaceuticals: Access, Innovation, and Consumer Welfare, National Bureau of Economic Research Working paper No. 9229. Cambridge, MA. NBER; 2002.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibUnstructured>Eurek SE Hatch-Waxman Reform and Accelerated Market Entry of Generic Drugs: Is Faster Necessarily Better? Duke L &amp; Tech Rev. 2003.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
